Computational drug screening for drug-resistant tuberculosis: advances, challenges, and future perspectives
- 1Department of Respiratory and Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University
- 2Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
- 3Department of Clinical Research Management, West China Hospital, Sichuan University
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis , remains a major global health challenge, further exacerbated by the rapid emergence of drug-resistant strains. Despite continuous efforts, the discovery of novel anti-TB agents has lagged behind the evolution of resistance, largely due to the limitations of conventional experimental pipelines and the growing biological complexity of the pathogen. In recent years, computational drug discovery approaches—including virtual screening, artificial intelligence (AI)-driven modeling, and hybrid computational frameworks—have substantially expanded the chemical space accessible for early-stage anti-TB research. However, their translational success remains limited. This discrepancy reflects a fundamental mismatch between target-centric computational paradigms and the multi-scale biological constraints of Mtb , including permeability barriers, efflux mechanisms, metabolic state heterogeneity, lesion-level pharmacokinetics, and regimen-dependent therapeutic effects. This review critically evaluates current computational strategies for anti-TB drug screening, with particular emphasis on their performance under TB-specific biological and resistance constraints. We further explore computational approaches designed to address drug-resistant Mtb , including resistance-aware compound design, host-directed therapy, and combination regimen modeling. Finally, we explore key limitations in current computational pipelines, including challenges in data quality, biological integration, and regimen-level modeling, and propose a shift toward biologically grounded, regimen-aware, and systems-level frameworks. Bridging the gap between in silico prediction and clinical efficacy will require integrating multi-scale biological realism into computational pipelines, enabling more reliable translation of computational advances into effective anti-TB therapeutics.
Related
- Challenges of Using a Bedaquiline-Based Regimen to Treat Multidrug-Resistant Tuberculosis in Pregnancy
- Cell-Free DNA-Based Blood Tests for Colorectal Cancer Screening: Current Advances, Challenges, and Future Perspectives
- Rapid simultaneous detection of katG S315T and rpoB S531L mutations for molecular screening of multidrug-resistant tuberculosis using a dual LAMP-lateral flow assay
- A rare case report of Rasmussen’s aneurysm in multidrug-resistant tuberculosis from Nepal
- Drug-Resistant Tuberculosis in Rural Eastern Cape: Integrating Whole-Genome Sequencing, Conceptual Transmission Modelling and Community-Based Participatory Research
BibTeX
@article{hu2026computational,
title = {{Computational drug screening for drug-resistant tuberculosis: advances, challenges, and future perspectives}},
author = {ShanShan Hu and Xiaoyu Li and Zahra Batool and Xin Zheng and Jiajia Dong and Chi Zhang and Yin Yang and Bairong Shen},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1808051},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1808051/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Computational drug screening for drug-resistant tuberculosis: advances, challenges, and future perspectives
AU - ShanShan Hu
AU - Xiaoyu Li
AU - Zahra Batool
AU - Xin Zheng
AU - Jiajia Dong
AU - Chi Zhang
AU - Yin Yang
AU - Bairong Shen
PY - 2026
DA - 2026/10/26
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1808051
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1808051/full
AB - Tuberculosis (TB), caused by Mycobacterium tuberculosis , remains a major global health challenge, further exacerbated by the rapid emergence of drug-resistant strains. Despite continuous efforts, the discovery of novel anti-TB agents has lagged behind the evolution of resistance, largely due to the limitations of conventional experimental pipelines and the growing biological complexity of the pathogen. In recent years, computational drug discovery approaches—including virtual screening, artificial intelligence (AI)-driven modeling, and hybrid computational frameworks—have substantially expanded the chemical space accessible for early-stage anti-TB research. However, their translational success remains limited. This discrepancy reflects a fundamental mismatch between target-centric computational paradigms and the multi-scale biological constraints of Mtb , including permeability barriers, efflux mechanisms, metabolic state heterogeneity, lesion-level pharmacokinetics, and regimen-dependent therapeutic effects. This review critically evaluates current computational strategies for anti-TB drug screening, with particular emphasis on their performance under TB-specific biological and resistance constraints. We further explore computational approaches designed to address drug-resistant Mtb , including resistance-aware compound design, host-directed therapy, and combination regimen modeling. Finally, we explore key limitations in current computational pipelines, including challenges in data quality, biological integration, and regimen-level modeling, and propose a shift toward biologically grounded, regimen-aware, and systems-level frameworks. Bridging the gap between in silico prediction and clinical efficacy will require integrating multi-scale biological realism into computational pipelines, enabling more reliable translation of computational advances into effective anti-TB therapeutics.
SN - 1663-9812
ER -